SE0201943D0 - New use - Google Patents

New use

Info

Publication number
SE0201943D0
SE0201943D0 SE0201943A SE0201943A SE0201943D0 SE 0201943 D0 SE0201943 D0 SE 0201943D0 SE 0201943 A SE0201943 A SE 0201943A SE 0201943 A SE0201943 A SE 0201943A SE 0201943 D0 SE0201943 D0 SE 0201943D0
Authority
SE
Sweden
Prior art keywords
antagonists
treatment
glutamate receptor
metabotropic glutamate
new use
Prior art date
Application number
SE0201943A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Lehmann
Jan Mattsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0201943(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201943A priority Critical patent/SE0201943D0/xx
Publication of SE0201943D0 publication Critical patent/SE0201943D0/xx
Priority to RU2005101411/15A priority patent/RU2324484C2/ru
Priority to SI200331220T priority patent/SI1513525T1/sl
Priority to CNB038141760A priority patent/CN100430056C/zh
Priority to AT03731333T priority patent/ATE395059T1/de
Priority to HK05107987.5A priority patent/HK1075833B/en
Priority to PT03731333T priority patent/PT1513525E/pt
Priority to NZ536559A priority patent/NZ536559A/en
Priority to UA20041210177A priority patent/UA81627C2/ru
Priority to JP2004515703A priority patent/JP4683920B2/ja
Priority to PL03372186A priority patent/PL372186A1/xx
Priority to DE60320990T priority patent/DE60320990D1/de
Priority to MXPA04012659A priority patent/MXPA04012659A/es
Priority to CA2489730A priority patent/CA2489730C/en
Priority to US10/517,869 priority patent/US7964609B2/en
Priority to BR0311759-6A priority patent/BR0311759A/pt
Priority to PCT/US2003/016223 priority patent/WO2004000316A1/en
Priority to AU2003241585A priority patent/AU2003241585B2/en
Priority to DK03731333T priority patent/DK1513525T3/da
Priority to ES03731333T priority patent/ES2304510T3/es
Priority to EP03731333A priority patent/EP1513525B1/en
Priority to IL16513804A priority patent/IL165138A0/xx
Priority to ZA200409908A priority patent/ZA200409908B/en
Priority to NO20050154A priority patent/NO20050154L/no
Priority to IS7654A priority patent/IS7654A/is
Priority to CY20081100527T priority patent/CY1107954T1/el
Priority to JP2010268162A priority patent/JP2011068669A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0201943A 2002-06-20 2002-06-20 New use SE0201943D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use
ES03731333T ES2304510T3 (es) 2002-06-20 2003-06-19 Uso de antagonistas de mglur5 para el tratamiento de gerd.
EP03731333A EP1513525B1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
DE60320990T DE60320990D1 (de) 2002-06-20 2003-06-19 Verwendung von mglur5 antagonisten zur behandlung von gastroesophagalen refluxen
US10/517,869 US7964609B2 (en) 2002-06-20 2003-06-19 Use of mGluR5 antagonists for the treatment of gerd
CNB038141760A CN100430056C (zh) 2002-06-20 2003-06-19 Mglur5拮抗剂在制备治疗gerd的药物中的用途
AT03731333T ATE395059T1 (de) 2002-06-20 2003-06-19 Verwendung von mglur5 antagonisten zur behandlung von gastroesophagalen refluxen
HK05107987.5A HK1075833B (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
PT03731333T PT1513525E (pt) 2002-06-20 2003-06-19 Utilização de antagonistas de mglur5 para o tratamento do refluxo gastroesofágico
NZ536559A NZ536559A (en) 2002-06-20 2003-06-19 Use of a metabotropic glutamate receptor 5 antagonist for the treatment of gastro-esphageal reflux disease
UA20041210177A UA81627C2 (ru) 2002-06-20 2003-06-19 Применение антагонистов mglur5 для лечения гастроэзофагеального рефлюксионного заболевания
JP2004515703A JP4683920B2 (ja) 2002-06-20 2003-06-19 Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用
PL03372186A PL372186A1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
RU2005101411/15A RU2324484C2 (ru) 2002-06-20 2003-06-19 Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты)
MXPA04012659A MXPA04012659A (es) 2002-06-20 2003-06-19 Uso de antagonistas de mglur5 para el tratamiento de gerd.
CA2489730A CA2489730C (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
SI200331220T SI1513525T1 (sl) 2002-06-20 2003-06-19 Uporaba antagonistov MGLUR5 za zdravljenje gastroezofagealne refluksne bolezni
BR0311759-6A BR0311759A (pt) 2002-06-20 2003-06-19 Usos de um antagonista do receptor 5 do glutamato metabotrópico ou um sal farmaceuticamente aceitável ou um isÈmero óptico do mesmo e métodos de inibição de relaxamentos transientes do esfìncter esofagiano inferior, de tratamento da doença do refluxo gastro-esofagiano, de prevenção do refluxo, de tratamento ou prevenção da regurgitação, de doença pulmonar, da asma, de laringites crÈnicas e de administração da falta de desenvolvimento
PCT/US2003/016223 WO2004000316A1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
AU2003241585A AU2003241585B2 (en) 2002-06-20 2003-06-19 Use of mGluR5 antagonists for the treatment of GERD
DK03731333T DK1513525T3 (da) 2002-06-20 2003-06-19 Anvendelse af MGLUR5-antagonister til behandling af GERD
IL16513804A IL165138A0 (en) 2002-06-20 2004-11-10 Use of mglur5 antagonists for the treatment of gerd
ZA200409908A ZA200409908B (en) 2002-06-20 2004-12-07 Use of MgIuR5 antagonists for the treatment of GERD
NO20050154A NO20050154L (no) 2002-06-20 2005-01-11 Anvendelse av MGLUR5-antagonister til behandling av GERD
IS7654A IS7654A (is) 2002-06-20 2005-01-19 Notkun MGLUR5 mótlyfja til meðhöndlunar á maga-vélindis-bakflæðissjúkdómum
CY20081100527T CY1107954T1 (el) 2002-06-20 2008-05-21 Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd
JP2010268162A JP2011068669A (ja) 2002-06-20 2010-12-01 Ｇｅｒｄの治療のためのｍｇｌｕｒ５アンタゴニストの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use

Publications (1)

Publication Number Publication Date
SE0201943D0 true SE0201943D0 (sv) 2002-06-20

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use

Country Status (24)

Country Link
EP (1) EP1513525B1 (enExample)
JP (2) JP4683920B2 (enExample)
CN (1) CN100430056C (enExample)
AT (1) ATE395059T1 (enExample)
AU (1) AU2003241585B2 (enExample)
BR (1) BR0311759A (enExample)
CA (1) CA2489730C (enExample)
CY (1) CY1107954T1 (enExample)
DE (1) DE60320990D1 (enExample)
DK (1) DK1513525T3 (enExample)
ES (1) ES2304510T3 (enExample)
IL (1) IL165138A0 (enExample)
IS (1) IS7654A (enExample)
MX (1) MXPA04012659A (enExample)
NO (1) NO20050154L (enExample)
NZ (1) NZ536559A (enExample)
PL (1) PL372186A1 (enExample)
PT (1) PT1513525E (enExample)
RU (1) RU2324484C2 (enExample)
SE (1) SE0201943D0 (enExample)
SI (1) SI1513525T1 (enExample)
UA (1) UA81627C2 (enExample)
WO (1) WO2004000316A1 (enExample)
ZA (1) ZA200409908B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
CN1918154A (zh) * 2004-02-18 2007-02-21 阿斯利康(瑞典)有限公司 多杂环化合物及其作为代谢型谷氨酸受体拮抗剂的用途
RU2006128445A (ru) * 2004-02-18 2008-03-27 Астразенека Аб (Se) Ацетилиновые пиперазиновые соединения и их применение в качестве антагонистов метаботропных глутаматных рецепторов
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
SI2001849T1 (sl) * 2006-03-29 2015-02-27 F. Hoffmann-La Roche Ag Derivati piridina in pirimidina kot antagonisti mglur2
KR20090061041A (ko) 2006-09-11 2009-06-15 노파르티스 아게 대사성 글루타메이트 수용체의 조절제로서의 니코틴산 유도체
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
EP2826478A1 (en) 2008-06-30 2015-01-21 Novartis AG Combinations comprising mglur modulators for the treatment of parkinson's disease
WO2011009890A2 (en) 2009-07-23 2011-01-27 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
EP2490691A1 (en) 2009-10-20 2012-08-29 Novartis AG Use of 1h-quinazoline-2,4-diones
RU2013103001A (ru) 2010-06-24 2014-07-27 Новартис Аг Применение 1н-хиназолин-2,4-дионов
US20140171448A1 (en) 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2013036224A1 (en) 2011-09-07 2013-03-14 Novartis Ag Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
BR112015016994A8 (pt) 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
US20220387410A1 (en) * 2019-11-05 2022-12-08 Claes Thulin 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594424B2 (en) * 1986-01-03 1990-03-08 University Of Melbourne, The Gastro-oesophageal reflux composition
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
JP2002515448A (ja) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン 食道逆流病の処置法
RU2144331C1 (ru) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Способ лечения хронического гиперпластического ларингита
CZ2002599A3 (cs) * 1999-08-19 2002-06-12 Nps Pharmaceuticals Inc. Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu
US7115630B2 (en) * 2000-10-02 2006-10-03 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists

Also Published As

Publication number Publication date
SI1513525T1 (sl) 2008-08-31
AU2003241585B2 (en) 2009-06-25
ZA200409908B (en) 2006-08-30
NO20050154L (no) 2005-01-11
MXPA04012659A (es) 2006-05-25
AU2003241585A1 (en) 2004-01-06
PL372186A1 (en) 2005-07-11
BR0311759A (pt) 2005-03-08
ES2304510T3 (es) 2008-10-16
PT1513525E (pt) 2008-06-24
DK1513525T3 (da) 2008-08-11
CN1662235A (zh) 2005-08-31
HK1075833A1 (en) 2005-12-30
RU2005101411A (ru) 2005-07-10
EP1513525A1 (en) 2005-03-16
JP2006507225A (ja) 2006-03-02
IS7654A (is) 2005-01-19
UA81627C2 (ru) 2008-01-25
CN100430056C (zh) 2008-11-05
CA2489730C (en) 2011-11-22
CY1107954T1 (el) 2013-09-04
IL165138A0 (en) 2005-12-18
RU2324484C2 (ru) 2008-05-20
WO2004000316A1 (en) 2003-12-31
JP4683920B2 (ja) 2011-05-18
DE60320990D1 (de) 2008-06-26
ATE395059T1 (de) 2008-05-15
JP2011068669A (ja) 2011-04-07
CA2489730A1 (en) 2003-12-31
NZ536559A (en) 2007-08-31
EP1513525B1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
CY1107954T1 (el) Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd
ATE301649T1 (de) Furan and thiophen derivate die menschliche peroxisome proliferator aktivierte receptoren aktivieren
NO20035367D0 (no) Modulatorer av peroksisomproliferatoraktiverte reseptorer (PPAR)
TW200716520A (en) 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
CY1110863T1 (el) Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
ATE442846T1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
ATE475640T1 (de) Antagonisten des opioidrezeptors
NO20075209L (no) Substituerte aryl 1,4-pyrazinderivater
ATE399175T1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
DE602005008471D1 (de) Aryloxyethylaminderivate mit einer kombination ausonin-wiederaufnahmehemmung
BR0108867A (pt) Antagonistas de receptor il-8
WO2003043619A8 (en) New use for the treatment of gastroesophageal reflux disease
ATE399164T1 (de) Antagonisten des opioidrezeptors
BR0000486A (pt) Antagonistas do neuropeptìdeo y
SE0303492D0 (sv) New use VII
SE0201939D0 (sv) New combination
SE0303491D0 (sv) New use VI
SE0303490D0 (sv) New use V
DE69922918D1 (de) Neuropeptid Y Antagonisten
NO20044507L (no) 1-oksa-3-aza-dibenzoazulener som inhibitorer av tumornekrosefaktorproduksjon og mellomprodukter for fremstilling derav